The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics is a clinical-stage biopharmaceutical company seeking to develop medicines in areas of oncology and infectious diseases, with a focus on breast cancer, other breast conditions and COVID-19. Co.'s drug under development for breast cancer and other breast conditions is Endoxifen which is being developed primarily in two settings: one to reduce tumor cell activity in breast cancer patients in the neoadjuvant setting, meaning prior to surgery; and another to reduce dense breast tissue in women. Co.'s two COVID-19 drugs under development are: AT-H201, an inhalation therapy for COVID-19 patients; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Company Name:  Atossa Therapeutics Inc
Stock buyback:  ATOS buyback
Website:  www.atossatherapeutics.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding ATOS:  2
Total Market Value Held by ETFs:  $9.47M
Total Market Capitalization:  $237.00M
% of Market Cap. Held by ETFs:  4.00%
March 28, 2024    4:22 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree ATOS Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Strong Buy (4.00 out of 4)
98th percentile
(ranked higher than approx. 98% of all stocks covered)

Analysts' Target Price:
ATOS Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Atossa Therapeutics Inc (ATOS) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.